Hirabayashi, Koichi
Du, Hongwei http://orcid.org/0000-0002-7997-4507
Xu, Yang
Shou, Peishun http://orcid.org/0000-0001-7685-7471
Zhou, Xin
Fucá, Giovanni
Landoni, Elisa
Sun, Chuang
Chen, Yuhui
Savoldo, Barbara
Dotti, Gianpietro http://orcid.org/0000-0002-2639-8526
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-18-1-0441)
Vicky Amidon Innovation Grant in Lung Cancer Research from the Lung Cancer Initiative of North Carolina
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R01-CA193140-03)
Article History
Received: 13 October 2020
Accepted: 14 July 2021
First Online: 23 September 2021
Competing interests
: G. Dotti is a paid consultant for Bellicum Pharmaceuticals, Tessa Therapeutics and Catamaran and reports receiving commercial research grants from Cell Medica and Bluebird Bio; B. Savoldo is a paid consultant for Tessa Therapeutics; G. Dotti and H. Du filed a patent for the CAR targeting B7-H3. No other competing interests were disclosed by the other authors.